Most investors are so busy looking at a stock’s market action that they don’t take a serious look at the…

Kyle Dennis · October 19, 2017

“Double bottoms” and “double tops” are terms that you ear tossed around by analysts that sound great, but that many…

Kyle Dennis · October 17, 2017

Kyle Dennis says that an upcoming Phase II data release in early November on OncoSec Medical Inc. (ONCS) has the…

RagingBull.com · October 13, 2017

The back story: Back in August, I told you that Eiger Biopharmaceuticals (EIGR) looked like a great opportunity. It was…

Kyle Dennis · October 12, 2017

When a publicly traded company decides to raise money through a secondary offering, it should give you pause. It’s not…

Kyle Dennis · October 6, 2017

The setup: Cempra, Inc. (CEMP) is a clinical-stage pharmaceutical company that develops differentiated anti-infective drugs. It has two lead products…

Kyle Dennis · October 6, 2017

Kyle Dennis of Biotech Breakouts.com made a nice 25 percent profit on Medicinova (MNOV) and was looking at trading the…

RagingBull.com · October 6, 2017

Secondary offerings are a way for a company to raise capital to grow and expand their operations. Where an initial…

Kyle Dennis · October 3, 2017

Kyle Dennis of BiotechBreakouts.com likes PTC Therapeutics Inc. (PTCT) ahead of an Oct. 24 FDA-driven catalyst that he believes could…

RagingBull.com · October 2, 2017

Support and resistance lines are the building blocks of technical trading, essential in identifying entry and exit points by showing…

Kyle Dennis · September 29, 2017

Anyone investing in biotech and pharma stocks knows that “clinical trials” mean “news that can move the stock.” But understanding…

Kyle Dennis · September 28, 2017

Stocks listed on national exchanges follow stringent requirements and must report specific data directly to the Securities and Exchange Commission….

Kyle Dennis · September 27, 2017

Kyle Dennis of BiotechBreakouts.com likes antibiotic company Cempra Inc., which has a Phase 2-3 data readout coming by the end…

RagingBull.com · September 25, 2017

The setup: MediciNova, Inc. (MNOV) has a Phase 2B trial for MN-166, ibudilast, indicated for progressive multiple sclerosis. The data…

Kyle Dennis · September 22, 2017

Kyle Dennis made Bellicum Pharmaceuticals (BLCM) the Biotech Breakout of the Week on MoneyLife with Chuck Jaffe, noting that the…

RagingBull.com · September 18, 2017